Stem Cell Qualification for Hepatic Lineage Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a method to qualify batches of undifferentiated adult stem cells capable of differentiating into functional hepatocyte-like cells, as existing methods struggle with variability and functionality in therapeutic applications.
Innovation Solution
A qualification method involving culturing undifferentiated adult stem cells in a hepatic differentiation medium, followed by functional assays such as Indocyanine green uptake, OATP1B1 expression, and marker detection to assess the cells' ability to differentiate into hepatocyte-like cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hepatocytes are used for liver transplantation, then reliable treatment for end-stage liver disease is achieved, but shortage of available organs, high cost, and risk of rejection occur
Solution Approach 1:
The patent uses stem cells as a copyable alternative to actual hepatocytes. Stem cells can be cultured and expanded in vitro to produce hepatocyte-like cells, creating a renewable source that replicates the function of natural hepatocytes without requiring donor organs. This resolves the contradiction by providing unlimited copies of functional liver cells.
Solution Approach 2:
The patent changes the biological parameter from mature hepatocytes to undifferentiated stem cells. This parameter change enables in vitro expansion and differentiation, transforming a limited resource (donor organs) into an expandable resource (stem cell cultures) that can be produced on demand.
2Ease of operation
If hepatocytes are cultured in vitro, then cell therapy is enabled, but low in vitro expansion ability and rapid loss of function occur
Solution Approach 1:
Instead of attempting to culture mature hepatocytes directly (which have poor expansion ability), the patent inverts the approach by first culturing undifferentiated stem cells that have high proliferation capacity, then differentiating them into hepatocyte-like cells. This reverses the traditional sequence and achieves both ease of culture and functional output.
Solution Approach 2:
The patent performs preliminary expansion of stem cells before differentiation into hepatocytes. By first multiplying the stem cell population under optimal growth conditions and then inducing differentiation, the method overcomes the limited expansion ability of mature hepatocytes while ensuring sufficient cell numbers for therapy.
3Productivity
If stem cells are used as alternative source, then easy in vitro expansion is achieved, but need for qualification method to ensure functionality arises
Solution Approach 1:
The patent implements a qualification method that uses functional assays (Indocyanine green uptake, OATP1B1 expression, albumin production) to provide feedback on the hepatocyte-like functionality of differentiated cells. This feedback mechanism ensures that only batches meeting functional criteria are released for therapeutic use, resolving the reliability concern.
Solution Approach 2:
The patent performs preliminary qualification testing on stem cell batches before they are used for therapeutic purposes. By assessing differentiation potential and functional markers in advance, the method ensures that only capable batches proceed to clinical application, preventing failure later in the treatment process.
4Reliability
If functional assays are performed to qualify stem cell batches, then therapeutic suitability is ensured, but additional testing time and complexity are introduced
Solution Approach 1:
The patent employs a panel of functional assays rather than a single test, using multiple complementary methods (Indocyanine green uptake, OATP1B1 expression, albumin production) to qualify stem cell batches. This partial approach to comprehensive testing ensures reliable qualification while managing time through parallel execution of assays.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method effectively identifies batches of stem cells capable of producing functional hepatocyte-like cells, ensuring their suitability for therapeutic use and establishing a reliable process for creating a Master Cell Bank.
Implementation Method 1
culturing undifferentiated adult stem cells in a hepatic differentiation medium, followed by functional assays such as Indocyanine green uptake, OATP1B1 expression, and marker detection to assess the cells' ability to differentiate into hepatocyte-like cells
Implementation Method 2
functional assays such as Indocyanine green uptake
Implementation Method 3
OATP1B1 expression
Data Source
Figure 1
Figure 2(a)~2(b)
Figure 2(c)
AI summary
The invention relates to a qualification method to qualify a batch of undifferentiated adult stem cells having the potential of differentiating along the hepatic lineage as pharmaceutically active, wherein pharmaceutically active indicates that the batch is actually capable of producing sufficiently differentiated and/or functional and/or viable hepatocyte-like cells, so that the undifferentiated adult stem cells in said batch or the extracellular vesicles (EVs) derived therefrom are suitable for use in the therapeutic treatment of a subject suffering from a health condition or disease or are suitable to establish a Master Cell Bank from which sufficiently differentiated and/or functional and/or viable hepatocyte-like cells may subsequently be produced.